vTv Therapeutics (NASDAQ:VTVT) – Equities researchers at Seaport Global Securities dropped their Q1 2018 earnings estimates for shares of vTv Therapeutics in a note issued to investors on Tuesday, April 10th. Seaport Global Securities analyst C. Davis now anticipates that the biotechnology company will post earnings per share of ($0.45) for the quarter, down from their previous estimate of ($0.30). Seaport Global Securities has a “Neutral” rating on the stock. Seaport Global Securities also issued estimates for vTv Therapeutics’ Q2 2018 earnings at ($0.26) EPS, Q3 2018 earnings at ($0.18) EPS, Q4 2018 earnings at ($0.16) EPS, FY2018 earnings at ($1.05) EPS, FY2019 earnings at ($0.48) EPS, FY2020 earnings at ($0.40) EPS and FY2022 earnings at ($0.32) EPS.
vTv Therapeutics (NASDAQ:VTVT) last released its earnings results on Tuesday, February 27th. The biotechnology company reported ($0.44) EPS for the quarter, missing analysts’ consensus estimates of ($0.41) by ($0.03). The firm had revenue of $0.23 million for the quarter, compared to analyst estimates of $0.10 million.
A number of other research firms have also recently commented on VTVT. Northland Securities began coverage on shares of vTv Therapeutics in a research note on Thursday, February 8th. They set an “outperform” rating and a $28.00 target price for the company. Roth Capital began coverage on shares of vTv Therapeutics in a research note on Thursday, March 8th. They set a “buy” rating and a $17.00 target price for the company. Zacks Investment Research cut shares of vTv Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, March 3rd. Canaccord Genuity set a $15.00 target price on shares of vTv Therapeutics and gave the stock a “buy” rating in a research note on Thursday, December 21st. Finally, Stifel Nicolaus cut shares of vTv Therapeutics from a “buy” rating to a “hold” rating in a research note on Tuesday. One investment analyst has rated the stock with a sell rating, six have given a hold rating and two have given a buy rating to the stock. The stock presently has a consensus rating of “Hold” and an average target price of $13.69.
VTVT stock opened at $0.71 on Thursday. The stock has a market cap of $106.97, a PE ratio of -0.43 and a beta of 1.74. The company has a debt-to-equity ratio of -0.10, a current ratio of 0.76 and a quick ratio of 0.76. vTv Therapeutics has a 52 week low of $0.65 and a 52 week high of $8.40.
A number of hedge funds and other institutional investors have recently made changes to their positions in the stock. State Street Corp grew its stake in vTv Therapeutics by 2.1% during the 2nd quarter. State Street Corp now owns 98,016 shares of the biotechnology company’s stock valued at $486,000 after acquiring an additional 1,976 shares in the last quarter. Creative Planning purchased a new stake in vTv Therapeutics during the 4th quarter valued at about $114,000. Millennium Management LLC purchased a new stake in vTv Therapeutics during the 4th quarter valued at about $377,000. JPMorgan Chase & Co. purchased a new stake in vTv Therapeutics during the 3rd quarter valued at about $481,000. Finally, Royce & Associates LP purchased a new stake in vTv Therapeutics during the 4th quarter valued at about $1,352,000. 11.20% of the stock is owned by institutional investors.
COPYRIGHT VIOLATION NOTICE: “Q1 2018 EPS Estimates for vTv Therapeutics Decreased by Seaport Global Securities (VTVT)” was first reported by Ticker Report and is the sole property of of Ticker Report. If you are viewing this report on another site, it was illegally copied and reposted in violation of United States and international copyright and trademark law. The legal version of this report can be read at www.tickerreport.com/banking-finance/3350631/q1-2018-eps-estimates-for-vtv-therapeutics-decreased-by-seaport-global-securities-vtvt.html.
vTv Therapeutics Company Profile
vTv Therapeutics Inc, a clinical-stage biopharmaceutical company, discovers, develops, and sells orally administered small molecule drug candidates worldwide. The company's drug candidates comprise azeliragon (TTP488), an orally administered, small molecule antagonist targeting the receptor for advanced glycation endproducts, which is in Phase III clinical trials for the treatment of Alzheimer's disease.